MarketCap
Facebook
X
TelegramAnnual report 2025
added 04-04-2026
Novartis AG ROCE Ratio 2011-2026 | NVS
Annual ROCE Ratio Novartis AG
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 10.25 | 10.08 | 7.25 | 24.55 | 7.66 | 8.32 | 11.27 | 10.92 | 11.49 | 11.66 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 24.55 | 7.25 | 11.35 |
Quarterly ROCE Ratio Novartis AG
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.68 | 2.34 | 6.02 | 7.37 | 7.37 | 3.69 | 6.18 | 4.98 | 4.98 | 2.49 | 5.58 | 6.18 | 6.18 | 3.09 | 5.22 | 4.26 | 4.26 | 2.13 | 5.39 | 6.52 | 6.52 | 3.26 | 3.26 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 7.37 | 2.13 | 4.87 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Burford Capital Limited
BUR
|
14.24 | $ 4.74 | 0.53 % | $ 761 M |  Britain |
 |
Cabaletta Bio
CABA
|
-153.72 | $ 3.33 | 2.15 % | $ 335 M |  USA |
 |
MorphoSys AG
MOR
|
2.89 | - | 2.43 % | $ 254 M |  Germany |
 |
Can-Fite BioPharma Ltd.
CANF
|
-146.69 | $ 3.07 | 0.49 % | $ 5.05 M |  Israel |
 |
Acorda Therapeutics
ACOR
|
167.74 | - | -24.86 % | $ 820 K | USA |
 |
Adverum Biotechnologies
ADVM
|
-196.79 | - | - | $ 86.2 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
63.56 | $ 332.58 | -2.01 % | $ 43.6 B | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-104.38 | $ 3.8 | 4.97 % | $ 9.14 B |  Australia |
 |
AlloVir
ALVR
|
-58.56 | - | 4.14 % | $ 49.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
17.36 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
-49.48 | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-325.06 | - | -13.47 % | $ 169 M | France |
 |
Aligos Therapeutics
ALGS
|
-164.32 | $ 7.51 | -14.07 % | $ 74.2 M | USA |
 |
Allakos
ALLK
|
-116.14 | - | - | $ 28.6 M | USA |
 |
Esperion Therapeutics
ESPR
|
-19.96 | $ 2.11 | 2.77 % | $ 439 M | USA |
 |
Evogene Ltd.
EVGN
|
-39.87 | $ 0.82 | - | $ 27.9 M | Israel |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-61.36 | - | -1.52 % | $ 24.7 M | USA |
 |
Applied Molecular Transport
AMTI
|
-209.11 | - | - | $ 10.1 M | USA |
|
Forte Biosciences
FBRX
|
-115.85 | $ 32.35 | -0.2 % | $ 419 M | USA |
 |
Midatech Pharma plc
MTP
|
-337.43 | - | -18.52 % | $ 27.3 M | Britain |
 |
Applied Therapeutics
APLT
|
394.73 | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
-163.42 | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
-664.7 | - | -13.39 % | $ 1.45 M | USA |
 |
Galapagos NV
GLPG
|
-3.51 | $ 28.99 | 0.36 % | $ 2.69 B |  Belgium |
 |
Amphastar Pharmaceuticals
AMPH
|
17.8 | $ 21.36 | -0.09 % | $ 998 M | USA |
 |
Genmab A/S
GMAB
|
31.74 | $ 29.02 | -0.14 % | $ 18.6 B |  Danmark |
 |
GT Biopharma
GTBP
|
-214.65 | $ 0.38 | -3.34 % | $ 2.1 M | USA |
 |
BioNTech SE
BNTX
|
-4.81 | $ 99.43 | 1.03 % | $ 27.2 B | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
15.18 | - | - | - |  Russia |
 |
Advaxis
ADXS
|
429.74 | - | -9.65 % | $ 45.9 M | USA |
 |
Hoth Therapeutics
HOTH
|
-119.38 | $ 0.68 | 4.58 % | $ 9.39 M | USA |
 |
Aeterna Zentaris
AEZS
|
-29.95 | - | 5.93 % | $ 314 M |  Canada |
 |
Harmony Biosciences Holdings
HRMY
|
20.45 | $ 29.37 | 0.27 % | $ 1.69 B | USA |
 |
AgeX Therapeutics
AGE
|
64924.32 | - | -10.17 % | $ 12.2 K | USA |
 |
ImmuCell Corporation
ICCC
|
4.28 | $ 7.61 | -1.55 % | $ 68.7 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-29.3 | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
72.06 | $ 1.54 | -1.28 % | $ 396 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-60.13 | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
211.07 | $ 4.18 | 0.6 % | $ 447 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-6.45 | $ 24.39 | -2.79 % | $ 3.1 B | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
163.63 | - | -2.5 % | $ 5.88 M | USA |
|
Immatics N.V.
IMTX
|
1.74 | $ 10.9 | -0.46 % | $ 686 M | Germany |
 |
AIkido Pharma
AIKI
|
-80.33 | - | 1.93 % | $ 17.4 M | USA |
 |
Incyte Corporation
INCY
|
29.32 | $ 97.43 | -0.27 % | $ 19 B | USA |
 |
BioDelivery Sciences International
BDSI
|
19.77 | - | -4.8 % | $ 255 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-151.88 | $ 1.46 | -1.49 % | $ 389 M | Britain |
 |
Aptose Biosciences
APTO
|
-46.69 | - | -45.71 % | $ 1.2 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
7.03 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Innate Pharma S.A.
IPHA
|
0.41 | $ 1.71 | 4.91 % | $ 235 M | France |